About Synteract
Synteract is a company based in Carlsbad (United States) founded in 1986 was acquired by Syneos Health in October 2020. Synteract has raised $3 million across 1 funding round from investors including Syneos Health, Gryphon Investors and Amulet Capital. The company has 378 employees as of December 31, 2020. Synteract has completed 3 acquisitions, including Cu-Tech, Harrison Clinical Research and KinderPharm. Synteract operates in a competitive market with competitors including Celgene, Syneos Health, Medelis WCCT Global, Emmes and Parexel, among others.
- Headquarter Carlsbad, United States
- Employees 378 as on 31 Dec, 2020
-
Sectors
Healthcare
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Synteract, Inc.
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Total Equity Funding
$3 M (USD)
in 1 rounds
-
Latest Funding Round
$3 M (USD), Series A
Feb 28, 2014
-
Investors
Syneos Health
& 2 more
-
Employee Count
378
as on Dec 31, 2020
-
Investments & Acquisitions
Cu-Tech
& 2 more
- Acquired by
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
People of Synteract
Unlock access to complete
Funding Insights of Synteract
Synteract has successfully raised a total of $3M through 1 strategic funding round. The most recent funding activity was a Series A round of $3 million completed in February 2014. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Synteract
Synteract has secured backing from 3 investors, including venture fund and institutional investors. Prominent investors backing the company include Syneos Health, Gryphon Investors and Amulet Capital.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
-
|
Locked | Locked | Locked | |
|
Amulet Capital is focused on healthcare private equity investments.
|
Locked | Locked | Locked | |
|
CRO clinical development services are provided by Syneos Health.
|
Locked | Locked | Locked |
Investor details for Synteract
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Synteract
Synteract has strategically engaged in corporate development activities, having acquired 3 companies. Notable acquisitions include Cu-Tech, Harrison Clinical Research and KinderPharm.
Investment portfolio details for Synteract
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Pediatric CRO services for drug development and formulations are specialized.
|
Locked | Locked | 2014 | Locked | |
|
Global full-service CRO with operations in Europe, Israel and the USA (acquired by Synteract in 2013)
|
Locked | Locked | 1999 | Locked | |
|
Full-service dermatology CRO for Phase I-IV clinical trials is operated.
|
Locked | Locked | 1993 | Locked |
Complete acquisition details for Synteract
Transaction dates, acquired stakes, disclosed values, domains, and locations require an active premium plan.
- Transaction dates
- Acquired stakes
- Disclosed values
- Domains and locations
Verified entity values are shown only after access is granted.
Financial Statements - Synteract
Detailed financials for Synteract
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Synteract Comparisons
Peer comparison for Synteract
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Synteract
Synteract operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Celgene, Syneos Health, Medelis WCCT Global, Emmes and Parexel, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Therapies for cancer and inflammatory diseases are developed.
|
|
| Locked | Locked | Locked |
CRO clinical development services are provided by Syneos Health.
|
|
| Locked | Locked | Locked |
Full-service CRO expertise in influenza and oncology research is offered.
|
|
| Locked | Locked | Locked |
Outsourced contract research organization services are provided to clients.
|
|
| Locked | Locked | Locked |
Full-service clinical research organization services are provided globally by Parexel.
|
|
| Locked | Locked | Locked |
Global full-service CRO services are delivered in over 80 countries.
|
Detailed competitors of Synteract
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Synteract
Complete news archive for Synteract
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Synteract
Synteract was founded in 1986 and raised its 1st funding round 28 years after it was founded.
Synteract is headquartered in Carlsbad, United States. It is registered at Carlsbad, California, United States.
Synteract is a funded company, having raised a total of $3M across 1 funding round to date.
As of Dec 31, 2020, the latest employee count at Synteract is 378.
In 2013, San Diego-based Synteract acquired Munich-based Harrison Clinical Research, forming SynteractHCR, an international contract research organisation. SynteractHCR is a global contract research organisation offering CRO services such as project management, clinical operations, medical writing, regulatory affairs and biostatistics etc., for phase I to phase IV research clinical trials. The therapeutic areas covered include oncology, CNS, infectious disease, endocrinology, cardiovascular and respiratory. The company claims to have conducted studies in 6 continents covering more than 60 countries. The company SynteractHCR was acquired by Amulet Capital Partners in May 2016.
Synteract's top competitors include Emmes, Syneos Health and ClinChoice.
Synteract has made 3 acquisitions, including Cu-Tech, Harrison Clinical Research, and KinderPharm.
Synteract has 3 investors. Key investors include Syneos Health, Gryphon Investors, and Amulet Capital.